Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608653 | 1.00 | ALOX15 (0.59) | ALOX15HSD17B10SIGMAR1SLC6A9CYP1A2 | |
| SCHEMBL1643026 | 1.00 | ALOX15 (0.59) | ALOX15HSD17B10SIGMAR1SLC6A9CYP1A2 | |
| SCHEMBL30291153 | 1.00 | ALOX15 (0.59) | ALOX15HSD17B10SIGMAR1SLC6A9CYP1A2 | |
| SCHEMBL24709144 | 0.90 | ALOX15 (0.48) | ALOX15HSD17B10SIGMAR1SLC6A9CYP1A2 | |
| SCHEMBL8033814 | 0.87 | SMN1; SMN2 (0.47) | ALOX15HSD17B10SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL20366148 | 0.87 | SMN1; SMN2 (0.47) | ALOX15HSD17B10SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL8512446 | 0.87 | SMN1; SMN2 (0.47) | ALOX15HSD17B10SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL8742080 | 0.85 | HSD17B10 (0.62) | ALOX15HSD17B10SLC6A9CYP1A2MAPK1 | |
| SCHEMBL23646017 | 0.85 | HSD17B10 (0.62) | ALOX15HSD17B10SLC6A9CYP1A2MAPK1 | |
| SCHEMBL8510307 | 0.85 | SIGMAR1 (0.47) | ALOX15HSD17B10SIGMAR1CYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | claimed |
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | claimed |
| EP-4648849-A1 | NMU RECEPTOR 2 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2025-11-19 | — | — | EP | claimed |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | claimed |
| WO-2025095856-A1 | SYSTEMS AND METHODS FOR COMBINED CARBON CAPTURE AND THERMAL ENERGY STORAGE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-05-08 | — | — | WO | claimed |
| WO-2025059775-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-27 | — | — | WO | claimed |
| WO-2025054727-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-20 | — | — | WO | claimed |
| EP-4499663-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2025-02-05 | — | — | EP | claimed |
| CN-119213011-A | Radiolabeled compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2024-12-27 | — | — | CN | claimed |
| US-20240350681-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-10-24 | — | — | US | claimed |
| EP-1844070-A1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| EP-1828240-A2 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | The Centre National de la Recherche Scientifique (FR) | 2007-09-05 | — | — | EP | claimed |
| WO-2006077035-A9 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2006-10-26 | — | — | WO | claimed |
| WO-2006077035-A1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | claimed |
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | DANHO WALEED | 2006-07-20 | — | — | US | claimed |
| WO-2006064133-A2 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-06-22 | — | — | WO | claimed |
| EP-1401863-A4 | SOMATOSTATIN-DOPAMINE CHIMERIC ANALOGS | SOD CONSEILS RECH APPLIC (FR) | 2006-04-26 | — | — | EP | claimed |
| CN-1514843-A | Somatostatin-dopamine chimeric analogs | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 2004-07-21 | — | — | CN | claimed |
| EP-1401863-A1 | SOMATOSTATIN-DOPAMINE CHIMERIC ANALOGS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2004-03-31 | — | — | EP | claimed |
| WO-2002100888-A1 | SOMATOSTATIN-DOPAMINE CHIMERIC ANALOGS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2002-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, GPR18 | ALOX15 894/4885HSD17B10 2488/4885SIGMAR1 1052/4885 |
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | NPY2R, NPY1R, NPY4R | ALOX15 3045/4885HSD17B10 2442/4885SIGMAR1 215/4885 |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | ALOX15 3399/4885HSD17B10 4254/4885SIGMAR1 558/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | ALOX15 3981/4885HSD17B10 4841/4885SIGMAR1 218/4885 |
| US-20240350681-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | MC1R, MC3R, MC5R | ALOX15 2647/4885HSD17B10 2867/4885SIGMAR1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.